CLINICAL_TRIALS
research
· 2025-07-28
Clinical Trial Update: hAM for Inferior RRD [NA]
Summary
A clinical trial is recruiting to evaluate hAM (human amniotic membrane) for treating inferior rhegmatogenous retinal detachment.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eye & ENT Hospital of Fudan University | Conditions: Rhegmatogenous Retinal Detachment | NA | Status: RECRUITING